Latest & greatest articles for ezetimibe

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ezetimibe or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ezetimibe and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ezetimibe

21. Ezetimibe plus a Statin after Acute Coronary Syndromes. Full Text available with Trip Pro

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444738 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1474-5 10.1056/NEJMc1509363 Patti Giuseppe G Cavallari Ilaria I eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV Simvastatin AIM IM N Engl J

2015 NEJM

22. Ezetimibe plus a Statin after Acute Coronary Syndromes. Full Text available with Trip Pro

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444739 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1475 10.1056/NEJMc1509363 Nunes José P L JP eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV Simvastatin AIM IM N Engl J Med. 2015 Jun 18;372

2015 NEJM

23. Ezetimibe plus a Statin after Acute Coronary Syndromes. Full Text available with Trip Pro

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444740 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1475-6 10.1056/NEJMc1509363 Richard Thibault T Lelubre Christophe C Vanhaeverbeek Michel M eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV

2015 NEJM

24. Ezetimibe plus a Statin after Acute Coronary Syndromes. Full Text available with Trip Pro

Ezetimibe plus a Statin after Acute Coronary Syndromes. 26444741 2015 10 08 2018 12 02 1533-4406 373 15 2015 10 08 The New England journal of medicine N. Engl. J. Med. Ezetimibe plus a Statin after Acute Coronary Syndromes. 1476 10.1056/NEJMc1509363 Singh Jagdeep S JS Struthers Allan D AD Lang Chim C CC eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticholesteremic Agents 0 Azetidines 0 Cholesterol, LDL 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors AGG2FN16EV Simvastatin

2015 NEJM

25. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia (Abstract)

Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia To evaluate the lipid-altering efficacy and safety of ezetimibe monotherapy in young children with heterozygous familial hypercholesterolemia (HeFH) or nonfamilial hypercholesterolemia (nonFH).One hundred thirty-eight children 6-10 years of age with diagnosed HeFH or clinically important nonFH (low-density lipoprotein cholesterol [LDL-C] ≥ 160 mg/dL [4.1 mmol/L]) were enrolled (...) into a multicenter, 12-week, randomized, double-blind, placebo-controlled study. Following screening/drug washout and a 5-week single-blind placebo-run-in with diet stabilization, subjects were randomized 2:1 to daily ezetimibe 10 mg (n = 93) or placebo (n = 45) for 12 weeks. Lipid-altering efficacy and safety were assessed in all treated patients.Overall, mean age was 8.3 years, 57% were girls, 80% were white, mean baseline LDL-C was 228 mg/dL (5.9 mmol/L), and 91% had HeFH. After 12 weeks, ezetimibe

2015 EvidenceUpdates Controlled trial quality: uncertain

26. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. Full Text available with Trip Pro

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known.We conducted a double-blind, randomized trial involving 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 (...) days and had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.6 mmol per liter) if they were receiving lipid-lowering therapy or 50 to 125 mg per deciliter (1.3 to 3.2 mmol per liter) if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The primary end point was a composite of cardiovascular death, nonfatal myocardial

2015 NEJM Controlled trial quality: predicted high

27. Randomised controlled trial: Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome

Randomised controlled trial: Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) . To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Ezetimibe provides incremental reduction in risk for cardiovascular events

2015 Evidence-Based Medicine

28. IMPROVE-IT - To add, or not to add ezetimibe EZETROL to moderate dose statin?

IMPROVE-IT - To add, or not to add ezetimibe EZETROL to moderate dose statin? RxFiles: Trial Summary www.RxFiles.ca - Dec 2014, Updated June 2015 Loren Regier BSP BA, Brent Jensen BSP IMPROVE-IT To add, or not to add ezetimibe EZETROL to moderate dose statin? What we already knew? ? Statins… have consistently demonstrated efficacy in lowering not only LDL, but risk of cardiovascular (CV) events +/- mortality in those with high CV risk. 1 ? Ezetimibe… 2 o has no evidence as monotherapy (...) -controlled trial design, the benefit could have been due to the statin alone. SHARP What IMPROVE-IT may add? ? Ezetimibe may modestly lower CV event risk when added to a moderate dose statin (simvastatin 40mg). IMPROVE-IT 3,4 n=18,144; stable-recent ACS, normal LDL median2.46 ? 1.4 vs 1.8mmol/L Ezetimibe 10mg +Simvastatin 40mg Simvastatin 40mg NNT P Comment Combination VYTORIN USA only used. Composite of CV death, MI, unstable angina requiring hospitalization, revascularization or stroke (1 ? Endpoint

2014 RxFiles

29. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. Full Text available with Trip Pro

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy.To evaluate the efficacy and tolerability of evolocumab when used in combination with a moderate- vs high-intensity statin.Phase 3, 12-week, randomized, double-blind, placebo (...) - and ezetimibe-controlled study conducted between January and December of 2013 in patients with primary hypercholesterolemia and mixed dyslipidemia at 198 sites in 17 countries.Patients (n = 2067) were randomized to 1 of 24 treatment groups in 2 steps. Patients were initially randomized to a daily, moderate-intensity (atorvastatin [10 mg], simvastatin [40 mg], or rosuvastatin [5 mg]) or high-intensity (atorvastatin [80 mg], rosuvastatin [40 mg]) statin. After a 4-week lipid-stabilization period, patients (n

2014 JAMA Controlled trial quality: predicted high

30. Ezetimibe and simvastatin (Inegy) for reduction of cardiovascular risk in coronary heart disease

Ezetimibe and simvastatin (Inegy) for reduction of cardiovascular risk in coronary heart disease Ezetimibe and simvastatin (Inegy) for reduction of cardiovascular risk in coronary heart disease Ezetimibe and simvastatin (Inegy) for reduction of cardiovascular risk in coronary heart disease NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation NIHR HSC. Ezetimibe and simvastatin (Inegy) for reduction of cardiovascular risk in coronary heart disease. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Azetidines; Coronary Diseases; Drug Combinations; Simvastatin Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning

2013 Health Technology Assessment (HTA) Database.

31. Liptruzet (ezetimibe and atorvastatin)

Liptruzet (ezetimibe and atorvastatin) Drug Approval Package: Liptruzet (ezetimibe and atorvastatin) NDA #200153 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Liptruzet (ezetimibe and atorvastatin) Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg Company: Merck Sharp & Dohme Corp. Application No.: 200153 Approval Date: 05/03/2013 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

2013 FDA - Drug Approval Package

32. Ezetimibe (Ezetrol) in combination with a statin for reduction of cardiovascular risk in coronary heart disease

Ezetimibe (Ezetrol) in combination with a statin for reduction of cardiovascular risk in coronary heart disease Ezetimibe (Ezetrol) in combination with a statin for reduction of cardiovascular risk in coronary heart disease Ezetimibe (Ezetrol) in combination with a statin for reduction of cardiovascular risk in coronary heart disease NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation NIHR HSC. Ezetimibe (Ezetrol) in combination with a statin for reduction of cardiovascular risk in coronary heart disease. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Anticholesteremic Agents; Azetidiness; Cardiovascular Diseases; Drug Therapy, Combination; Hydroxymethylglutaryl-CoA Reductase Inhibitors Language Published English

2013 Health Technology Assessment (HTA) Database.

33. Ezetimibe for hypercholesterolaemia

Ezetimibe for hypercholesterolaemia Executive Summary IQWiG Reports - Commission No. A10-02 Ezetimibe for hypercholesterolaemia 1 1 Translation of the executive summary of the final report “Ezetimib bei Hypercholesterinämie” (Version 1.0; Status: 18.07.2011). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Executive summary of final report A10-02 Version 1.0 (...) Ezetimibe for hypercholesterolaemia 18.07.2011 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ezetimibe for hypercholesterolaemia Contracting agency: Federal Joint Committee Commission awarded on: 20.05.2010 Internal Commission No.: A10-02 Address of publisher: Institute for Quality and Efficiency in Health Care Dillenburger Str. 27 51105 Cologne Germany Tel: +49-(0)221/35685-0 Fax: +49-(0)221

2012 Institute for Quality and Efficiency in Healthcare (IQWiG)

34. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlle (Abstract)

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlle Inhibition of proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) resulted in large reductions of low-density lipoprotein cholesterol (LDL-C) in phase 1 trials. We assessed the efficacy and safety of various doses and dosing (...) intervals of REGN727, a monoclonal antibody to PCSK9, added to statins, to further lower LDL-C in patients with heterozygous familial hypercholesterolaemia.This multicentre, randomised, placebo-controlled phase 2 trial was done at 16 lipid clinics in the USA and Canada. Between Jan 18, 2011, and Nov 7, 2011, we enrolled adults with heterozygous familial hypercholesterolaemia and LDL-C concentrations of 2·6 mmol/L or higher on stable diet and statin dose, with or without ezetimibe. Patients were randomly

2012 Lancet Controlled trial quality: predicted high

35. Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia

Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 NHS Economic Evaluation Database.

36. SHARP: Study of Heart & Renal Protection - The Effects of Lowering LDL Cholesterol with Simvastatin plus Ezetimibe in Patients with Chronic Kidney Disease

SHARP: Study of Heart & Renal Protection - The Effects of Lowering LDL Cholesterol with Simvastatin plus Ezetimibe in Patients with Chronic Kidney Disease SHARP: Study of Heart & Renal Protection 1-2 The Effects of Lowering LDL Cholesterol with Simvastatin plus Ezetimibe in Patients with Chronic Kidney Disease TRIAL BACKGROUND • Prevalence of CKD is steadily climbing in Canada. CVD is the leading cause of death in CKD ~10-30 fold higher than general population . • In late-stage CKD GFR 150umol (...) ) Jill Hall, BScPharm & Aleesa Carter, BSP, PharmD Candidates COMMENTS • Revised 1 ° outcome is likely the better outcome since it allows determination of benefit from statins by looking at outcomes statins are known to impact; controversy settled when results between the 2 outcomes were similar and power was adequate for both • Cannot conclude if benefit secondary to addition of ezetimibe to statin therapy vs. statin therapy alone; however, lack of clinical benefit despite expected LDL reduction

2011 RxFiles

37. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis

Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

38. [Ezetimibe for hypercholesterolaemia]

[Ezetimibe for hypercholesterolaemia] Ezetimib bei Hypercholesterinämie [Ezetimibe for hypercholesterolaemia] Ezetimib bei Hypercholesterinämie [Ezetimibe for hypercholesterolaemia] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Ezetimib bei Hypercholesterinämie. [Ezetimibe for hypercholesterolaemia] Cologne: Institut fuer (...) Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 90. 2011 Authors' objectives In its letter of 20 May 2010, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to assess ezetimibe (in mono- or combination therapy) in patients with hypercholesterolaemia. Authors' conclusions In patients with hypercholesterolaemia there is no proof of a benefit or harm from ezetimibe therapy compared with placebo. This applies both

2011 Health Technology Assessment (HTA) Database.

39. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Full Text available with Trip Pro

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lowering LDL cholesterol with statin regimens reduces the risk of myocardial infarction, ischaemic stroke, and the need for coronary revascularisation in people without kidney disease, but its effects in people with moderate-to-severe kidney disease are uncertain. The SHARP trial aimed to assess the efficacy (...) and safety of the combination of simvastatin plus ezetimibe in such patients.This randomised double-blind trial included 9270 patients with chronic kidney disease (3023 on dialysis and 6247 not) with no known history of myocardial infarction or coronary revascularisation. Patients were randomly assigned to simvastatin 20 mg plus ezetimibe 10 mg daily versus matching placebo. The key prespecified outcome was first major atherosclerotic event (non-fatal myocardial infarction or coronary death, non

2011 Lancet Controlled trial quality: predicted high

40. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults >/=65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study) (Abstract)

Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults >/=65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study) Higher than 80% of coronary heart disease-related mortality occurs in patients ≥65 years of age. Guidelines recommend low-density lipoprotein (LDL) cholesterol targets for these at-risk patients; however, few clinical studies have evaluated lipid-lowering strategies (...) specifically in older adults. This multicenter, 12-week, randomized, double-blind, parallel-group trial evaluated the efficacy and safety of the usual starting dose of ezetimibe/simvastatin (10/20 mg) versus atorvastatin 10 or 20 mg and the next higher dose of ezetimibe/simvastatin (10/40 mg) versus atorvastatin 40 mg in 1,289 hypercholesterolemic patients ≥65 years of age with or without cardiovascular disease. Patients randomized to ezetimibe/simvastatin had greater percent decreases in LDL cholesterol

2010 EvidenceUpdates Controlled trial quality: uncertain